Current Status and Limitation of Direct Oral Anticoagulants Testing

Authors: Mruthunjaya AKV and Torriero AAJ*

DOI: 10.23880/ijbp-16000204

Volume 7, Issue 1

Abstract

Direct oral anticoagulants (DOACs) are a class of drugs that are prescribed for preventing and treating thromboembolism. The DOACs have better efficacy and do not require regular monitoring. However, in emergency scenarios where patients suffer from impaired renal function, haemorrhage, and ischemic stroke, it is critical to know that the drug concentration is ≤30 ng mL-1 before making any life-saving decisions. Traditional laboratory tests are insensitive to low concentrations of DOACs. Unlike traditional laboratory-based coagulation assays, point-of-care (POC) testing is better suited for this application. This review summarises the recent advancements in DOACs testing, focusing on the need for a whole blood-based electrochemical POC assay to quantify DOACs in an emergency care setting.

Keywords: Direct Oral Anticoagulants; FXa; Dabigatran; Rivaroxaban; Apixaban

View PDF